To explore insured impacts further, and how they may translate to your policyholders, reach out to your local RGA representative
Laurel Campbell, with West Tennessee Medical Group Primary Care & Pediatrics | Dyersburg, shares some insight below
Gastrointestinal adverse effects were more commonly reported in the GLP-1 receptor agonist groups, while genital mycotic infections and volume depletion-related adverse effects were more frequently observed in the SGLT2 inhibitor groups
Generic Ozempic makes debut in India ahead of Canada, where it became legal months ago Manufacturers have been barred from direct-to-consumer advertising, including surrogate and influencer-led promotion, although anti-obesity media campaigns have surfaced
Screening for diabetic kidney disease Early-stage DKD is usually a silent disease, with minimal clinical manifestations until the patient has progressed to an advanced stage of kidney disease
GLP-1RA Liraglutide Semaglutide Efpeglenatide Glucose lowering effect CV system protection effect Kidney protection effect Nonalcoholic fatty liver disease GIP/GLP1 receptor coagonists: tirzepatide Amylin/GLP1 receptor coagonists: CagriSema (cagrilintide+semaglutide) Glucagon/GLP1 receptor coagonists: survodutide GIP/GLP1/glucagon receptor triple coagonists: retatrutide Obesity is a disease that can be treated with targeted pharmacotherapy in addition to lifestyle modification and behavioral interventions